697 Xenograft Model Service for ALL

The 697 cell line offers a robust and clinically relevant in vivo platform for investigating Acute lymphoblastic leukemia (ALL), specifically for evaluating targeted therapeutic interventions in B-cell precursor malignancies. As a specialized pre-clinical contract research organization, Alfa Cytology provides an integrated, high-precision 697 Xenograft Model Service, meticulously engineered to deliver reproducible, audit-ready datasets that accelerate your ALL drug discovery and development pipeline.

Overview of 697 Xenograft Model for ALL

The 697 xenograft model is an established in vivo translational tool widely utilized in hematological oncology research for the study of ALL. By transplanting human 697 lymphoblastoid cells into highly permissive, immunodeficient mouse hosts, this model effectively reproduces the systemic dissemination, aggressive bone marrow infiltration, and distinct peripheral blood pathophysiological profiles characteristic of refractory human ALL.

Biologically, the 697 model is highly valued for its stable engraftment parameters and proliferative consistency, offering pre-clinical researchers a reliable experimental window for conducting rigorous pharmacological assessments. The platform preserves key human B-cell precursor molecular features, including lineage-specific surface markers and altered intracellular signaling cascades---such as those involving specific chromosomal translocations---which are essential for evaluating the anti-leukemic potency of targeted small-molecule inhibitors, monoclonal antibodies, and combination therapeutic regimens. This model facilitates a comprehensive understanding of leukemic progression dynamics in an in vivo environment, ensuring that therapeutic responses are evaluated with high physiological relevance.

Fig 1. OSU-2S mediates cytotoxicity and cell cycle arrest in B-ALL. (Goswami S, et al., 2022)

Cell Line Information: 697

The 697 cell line was established from a patient with ALL and is widely recognized for its stable phenotype and suitability for studying B-cell precursor malignancies. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a consistent lymphoblastoid morphology.

Our Services

Workflow of 697 Xenograft Model Construction

• Cell Culture & Quality Control: Human 697 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability 697 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific lymphoid markers in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 2. 697 Xenograft Model Construction Workflow

Case Study - 697 Xenograft Model Development

A pre-clinical validation study was conducted using the 697 xenograft model to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting leukemia-associated survival signaling in ALL. Following precision intravenous inoculation of human 697 cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals in the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted ALL therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse hematological and lymphoid lineages, providing highly reproducible in vivo translational platforms for complex leukemia research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive FACS metrics and robust statistical validations.

Contact us

Accelerating your ALL pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our 697 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.